NovaBay Pharmaceuticals, Inc. (NBY) Issues Earnings Results

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) posted its earnings results on Thursday. The company reported ($0.11) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.01, reports. NovaBay Pharmaceuticals had a negative return on equity of 280.84% and a negative net margin of 108.38%. The company had revenue of $4.12 million for the quarter, compared to the consensus estimate of $4.57 million.

Shares of NovaBay Pharmaceuticals (NBY) opened at 4.35 on Friday. The stock’s market cap is $66.59 million. NovaBay Pharmaceuticals has a 12-month low of $2.25 and a 12-month high of $5.29. The company has a 50 day moving average price of $4.05 and a 200 day moving average price of $3.62.

A number of research firms have commented on NBY. Maxim Group restated a “hold” rating on shares of NovaBay Pharmaceuticals in a research report on Saturday, May 13th. HC Wainwright set a $6.00 target price on NovaBay Pharmaceuticals and gave the company a “buy” rating in a research report on Friday. Zacks Investment Research downgraded NovaBay Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Finally, Roth Capital set a $6.00 target price on NovaBay Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, June 20th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $7.00.

COPYRIGHT VIOLATION WARNING: “NovaBay Pharmaceuticals, Inc. (NBY) Issues Earnings Results” was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.

What are top analysts saying about NovaBay Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NovaBay Pharmaceuticals Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit